Lead Product(s) : Tranexamic Acid
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 02, 2024
Lead Product(s) : Tranexamic Acid
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bentracimab
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : PhaseBio Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Details : BioVectra will provide its integrated CDMO services for the manufacturing of the active pharmaceutical ingredient (API) of bentracimab for use in PhaseBio’s ongoing global clinical trials and for global commercial use upon regulatory approval.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
November 03, 2021
Lead Product(s) : Bentracimab
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : PhaseBio Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement